CurrentUnitedHealthcarePolicy 2026 P 1152-14

Cosentyx (secukinumab) prior authorization

UnitedHealthcare prior authorization/notification policy for Cosentyx (secukinumab) prefilled syringe or Sensoready pen, specifying initial and reauthorization clinical criteria for multiple labeled indications and program operational notes. Effective for use starting 2026-04-01.

Policy Summary

PayerUnitedHealthcare

PolicyCosentyx (secukinumab) prior authorization

Policy CodePolicy 2026 P 1152-14

Change TypeAnnual review; wording/examples updated

Effective DateApr 1, 2026

Next Review Date

Key ActionPrior authorization/notification is required for Cosentyx through UnitedHealthcare; authorizations are issued for 12 months for approved indications.

POLICY UPDATE CHANGES

Annual review with updated not used in combination verbiage and examples; no change to clinical intent.

Coverage criteria for hidradenitis suppurativa added.

Non-radiographic axial spondyloarthritis indication added.

Psoriatic arthritis and ankylosing spondylitis indications added.

7Covered Indications (listed)

12 monthsAuthorization Duration

2026-04-01Policy Effective

Coverage Summary & Scope

Scope: UnitedHealthcare prior authorization/notification policy for Cosentyx (secukinumab) prefilled syringe or Sensoready pen, specifying initial and reauthorization clinical criteria for multiple labeled indications and program operational notes. Effective date: 2026-04-01.

Coverage stance: Covered with criteria. High-level covered indications include: moderate to severe plaque psoriasis (age ≥6), active psoriatic arthritis (age ≥2), ankylosing spondylitis, non-radiographic axial spondyloarthritis, enthesitis-related arthritis (age ≥4), and moderate to severe hidradenitis suppurativa. Authorization durations are issued for 12 months when approved.

Key policy facts

Policy number2026 P 1152-14

Effective date2026-04-01

Last review2026-01-01

Authorization duration12 months

Covered indication count7